Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 13, 2025 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases

Initiate a suite of clinical trials in 2025 intended to support global registration of NX-5948 for the treatment of chronic lymphocytic leukemia Expand the development of NX-5948 in additional...
June 16, 2024 05:30 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)

Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and...
November 02, 2023 08:28 ET | Source: Advanced Catheter Therapies

Occlusion Perfusion Catheter Demonstrates Superior Performance in PAD Drug Delivery

Researchers successfully demonstrate the delivery of liquid sirolimus into the arterial wall using the OPC, which can also be used for paclitaxel BTK.
September 13, 2023 09:23 ET | Source: The Insight Partners

Coronary Stents Market worth $13.87 Billion by 2025 - Exclusive Report by The Insight Partners

Pune, India, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Coronary stents are a kind of little mesh metal tubes that are developed for providing support to the weakened arteries within the heart. The coronary...
May 21, 2020 07:00 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Enters Into Binding Term Sheet to Acquire Exclusive Rights to Abivertinib with Completed Registrational Trial Data in Non-Small Cell Lung Cancer

Novel TKI compound with dual selective targeting of mutant forms of EGFR and BTKMore than 600 patients have been treated with the compound across studies, with over 200 patients in the completed...
February 29, 2016 06:55 ET | Source: ArQule, Inc.

ArQule Announces $15.3 Million Registered Direct Offering of Common Stock

BURLINGTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced it has entered into definitive agreements with certain institutional and accredited investors to raise...